---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-020389"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:44:58.038676+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q1 net loss $49M on flat revenue; completes $150M vitaCare sale

## Summary
- Total net product revenue $19.3M, down slightly from $19.6M Q1 2021.
- Net loss $49.0M ($5.69 per share) vs $39.4M loss year ago; includes $8.4M debt extinguishment loss.
- Cash $30.4M at March 31, down from $65.1M Dec 2021; used $120M vitaCare proceeds to reduce debt.
- ANNOVERA prescriptions up 27% YoY to 8,014; new prescribers up 16% YoY.
- Completed $150M divestiture of vitaCare in five weeks; $16M PIK fee waived.

## SEC filing metadata
- accession: 0001564590-22-020389
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459022020389/0001564590-22-020389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459022020389/txmd-8k_20220516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-020389
- JSON: https://secwatch.observer/filing/0001564590-22-020389.json
- Plain text: https://secwatch.observer/filing/0001564590-22-020389.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.